TL;DR Immunotherapy with pembrolizumab combined with chemotherapy achieves 23.0-month median overall survival versus 16.1 months with chemotherapy alone for PD-L1 positive TNBC (CPS ≥10) [7] Pi Cancer Care provides personalized triple-negative breast cancer treatment protocols through multidisciplinary teams coordinating immunotherapy, targeted therapy, and chemotherapy options based on individual tumor profiling PARP inhibitors like olaparib show significant benefit for germ